<DOC>
	<DOC>NCT01903265</DOC>
	<brief_summary>TNX-102 capsules [formerly known as very low dose (VLD) cyclobenzaprine] at bedtime have shown promise as a treatment of fibromyalgia, but the drug required new formulation technology for bedtime use. The present trial was designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.</brief_summary>
	<brief_title>BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>Diagnosis of primary Fibromyalgia (ACR criteria) Male or female 1865 years old For patients with major depressive disorders only: clinically stable, no suicidal risk and stable antidepressent therapy Willing and able to withdraw specific therapies (ask PI) Medically acceptable form of contraception (female only) Signed informed consent Arthritis, lupus and other systemic autoimmune diseases Regional or persistent pain that could interfere with assessment of fibromyalgia pain Bipolar and psychotic disorders Increased risk of suicide Significant clinical (cardiac, systemic infection, systemic corticosteroid requirement, drug/alcohol abuse) or laboratory abnormalities. Inability to washoff specific medications (ask PI) Known hypersensitivity to cyclobenzaprine Others: seizure disorders, sleep apnea, continuous positive airway pressure (CPAP) use, BMI&gt;40</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pain</keyword>
	<keyword>sleep</keyword>
</DOC>